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Targeted cancer therapy requires the rapid and accurate identiﬁcation of genetic
abnormalities predictive of therapeutic response. We sought to develop a high-
throughput genotyping platform that would allow prospective patient selection
to the best available therapies, and that could readily and inexpensively be
adopted by most clinical laboratories. We developed a highly sensitive multi-
plexed clinical assay that performs very well with nucleic acid derived from
formalin ﬁxation and parafﬁn embedding (FFPE) tissue, and tests for 120
previously described mutations in 13 cancer genes. Genetic proﬁling of 250
primary tumours was consistent with the documented oncogene mutational
spectrum and identiﬁed rare events in some cancer types. The assay is currently
being used for clinical testing of tumour samples and contributing to cancer
patient management. This work therefore establishes a platform for real-time
targeted genotyping that can be widely adopted. We expect that efforts like this
one will play an increasingly important role in cancer management.
INTRODUCTION
The clinical management of cancer patients has traditionally
relied on chemotherapeutic choices that are mostly dictated by
pathologictumourhistologyandorganoforigin.Inrecentyears,
major efforts to deﬁne the molecular causes of cancer have
revealed a wide number of genetic aberrations (Davies et al,
2005; Ding et al, 2008; Greenman et al, 2007; Rikova et al, 2007;
Sjoblom et al, 2006; Stephens et al, 2005; Thomas et al, 2007;
Woodetal,2007).Asmallsubsetofthesedefects,usuallyreferred
to as ‘drivers’, is frequently present across cancer types and
appears to be essential for oncogenesis and tumour progression
(Greenman et al, 2007). A new generation of drugs has been
developed to selectively target such cancer-promoting pathways,
(Drukeret al, 2001; Hanahan & Weinberg, 2000;Weinstein, 2000)
and hence treatment dictated by genetic markers is starting to
complement the more conventional therapeutic approaches.
While the clinical beneﬁt observed with some targeted agents
is encouraging, it has become clear that for such strategies to be
successful, it will be necessary to identify the patient population
carrying the genetic abnormalities targeted by each drug
(McDermott et al, 2007; Sos et al, 2009). In advanced non-
small cell lung cancer (NSCLC), activating mutations in the
region encoding the kinase domain of the epidermal growth
factor receptor (EGFR) gene predict tumour sensitivity to the
tyrosine kinase inhibitors (TKI) erlotinib and geﬁtinib (Lynch et
al, 2004; Paez et al, 2004; Pao et al, 2004; Sordella et al, 2004).
Since NSCLC patients harbouring EGFR mutations beneﬁt from
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standard chemotherapy (Mok et al, 2009), and only a small
fraction of NSCLCs harbour these mutations, prospective
screening for EGFR mutations at the time of diagnosis is
becoming common practice (Sharma et al, 2007). Equally
important is the identiﬁcation of mutations that render tumours
resistant to therapy. Activating mutations in KRAS predict
resistance to EGFR TKI treatment in NSCLC (Pao et al, 2005b). In
metastatic colorectal cancer, mutations in KRAS, BRAF and
PIK3CA are associated with resistance to treatment with
monoclonal antibodies cetuximab and panitumumab, which
target the extracellular domain of EGFR (Di Nicolantonio et al,
2008; Lievre et al, 2006; Sartore-Bianchi et al, 2009). Similarly,
in breast cancer, oncogenic mutations in PIK3CA or low levels of
PTEN expression, may confer resistance to treatment with
trastuzumab,amonoclonalantibodythattargetstheHER2/NEU
receptor (Berns et al, 2007).
As the repertoire of selective therapeutic compounds
continues to expand, the need to evaluate larger numbers of
geneticmutations willbeamajorchallenge(Chin&Gray,2008).
In addition to the dilemma of selecting the most relevant
abnormalities, the tissue samples themselves pose many
obstacles, including minute specimens derived from small core
biopsies, poor quality fragmented nucleic acid due to the
formalin ﬁxation and parafﬁn embedding (FFPE) required for
histology-based diagnosis (Srinivasan et al, 2002), and hetero-
geneous tumour samples comprised of normal tissue and
cancerous cells which dilute the mutant alleles of interest. Thus,
a useful clinical assay will have to: (1) be multiplexed, to
maximize information retrieval from limited tissue; (2) perform
well with FFPE-derived material and (3) be sensitive enough to
detect low-level mutations. Additionally, the turn-around-time
for the entire specimen processing and mutation detection
platform has to be quick, in order to integrate into the rapid pace
of clinical decision making and impact patient management.
Taking all of these constraints into account, we developed a
robust and highly sensitive tumour genotyping assay that is
currently being used for real-time testing of tumours, and
assisting physicians in directing their cancerpatients tothe most
appropriate targeted therapies.
RESULTS
Assay design and validation
In order to develop a robust assay for clinical tumour
genotyping, several high-throughput platforms were evaluated
for the ability to detect low-level mutations in DNA extracted
from FFPE tissues. The SNaPshot assay from Applied Biosys-
tems consisting of a multiplexed PCR step followed by a single-
base extension reaction that generates allele-speciﬁc ﬂuores-
cently labelled probes (Fig 1) was ultimately selected given its
low background noise, high sensitivity, and good performance
with FFPE-derived DNA in a multiplexed setting. Moreover,
genetic analysis using the SNaPshot methodology follows a
simple workﬂow,withtheonly majorinstrumentation requirement
being a capillary electrophoresis automated DNA sequencer. The
SNaPshot system is particularly attractive because virtually all
clinical laboratories already have at least one of these
sequencers, hence avoiding additional capital expenses and
facilitating rapid implementation by most clinical testing sites.
We designed assays to detect recurrent mutations in some of
the most important cancer genes, many of which activate cancer
signalling pathways that are currently targeted by either Food
and Drug Administration (FDA)-approved therapies or by
agents in advanced stages of clinical development (Table 1).
Our genotyping platform consists of eight multiplexed reactions
that query 58 commonly mutated loci within 13 key cancer
genes.Since multiple nucleotidevariants havebeen described at
most of these sites, the test can detect 120 previously described
mutations (Supporting Information Table S1). We focused
predominantly on oncogenes over tumour suppressors because
aberrantly activated oncogenes are preferential targets for
pharmacologic inhibition, and gain-of-function mutations in
oncogenes are usually limited to a small set of codons.
Accordingly, our assay captures 94–99% of the mutation
frequency described for the BRAF, KRAS and JAK2 oncogenes,
which are frequently mutated in very few hotspots. Represen-
tative spectra of all eight SNaPshot genotyping panels are
depicted in Supporting Information Fig S1, which illustrates the
good performance of the assay with both high-quality, commer-
cially available genomic DNA (A) and total nucleic acid extracted
from FFPE primary tumour tissue from patients (B).
Assay validation was carried out with control DNA harbour-
ing the mutations of interest, which included: primary tumour
DNA, cancer cell line DNA and custom-designed synthetic
oligonucleotides (Supporting Information Table S1). All SNaP-
shot assays identiﬁed the expected mutations. In addition,
allele-speciﬁcassaysthatcouldbevalidatedusinggenomicDNA
were assessed for sensitivity, which ranged from 11.4 to 1.4%
and was on average approximately 5% (Supporting Information
Fig S2) an improvement over direct sequencing that is reported
to have a sensitivity of about 20% (Hughes et al, 2006). Since
allele-speciﬁc detection methods test a sequence change at one
site, we would not anticipate the sensitivity of each assay to be
affected by the mechanism that caused the mutation (point
mutationvs.insertionordeletion).Ourownexperiencewiththe
SNaPshot system supports this hypothesis. The sensitivity data
summarized in Supporting Information Fig S2 includes 44
assays (39 point mutations and 5 deletions) and the average
sensitivity for the deletions (4.69%) was very similar to the
average sensitivity for all assays (4.64%).
As an example of validation and sensitivity testing, Fig 2
illustrates SNaPshot analysis for two clinically relevant muta-
tions, KRAS G12D and EGFR T790M, both of which confer
resistance to anti-EGFR therapy. In each case, sensitivity was
determined using DNA from a cancer cell line harbouring the
mutation of interest, serially diluted with commercially
available wild-type DNA. The A427 lung carcinoma cell line
was used to detect the highly prevalent KRAS G12D mutation
(Fig 2A) (Bamford et al, 2004) and the NCI-H1975 lung
adenocarcinoma cell line was used to identify the EGFR T790M
mutation (Fig 2B), which represents the most commonly
described mechanism of acquired resistance to EGFR TKIs in
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instances, assay sensitivity was approximately 3% and data
quality was very comparable to traditional Sanger sequencing
analysis (panels on the right). A detailed illustration of the
process used to calculate assay sensitivity for these two cases is
shown in Supporting Information Fig S3. Of note, the use of
ﬂuorescently labelled probes in the SNaPshot assay enables
allele recognition to be contingent on two parameters: slightly
different masses and distinct colour readouts. These features
facilitate the ability to distinguish low-level mutations from
background noise. Finally, while 75% of the assays (33 out of
44) shown in Supporting Information Fig S2 were highly
sensitive detecting levels of mutant allele of  5%, when
analysing samples of unknown genotype we typically use a
mutant allele cut-off of 10%, which in our experience is a
conservative value that allows us to conﬁdently call a mutation
(detailed scoring guidelines are provided as Supporting
Information). Additional sensitivity data and examples of assay
validation using synthetic oligonucleotide probes are illustrated
in Supporting Information Figs S4 and S5.
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Figure 1. Schematic representation of SNaPshot genotyping.
A. The SNaPshot system follows a straightforward protocol and uses infrastructure already existent in most clinical laboratories. This method consists of a
multiplexed PCR step, followedbya single-baseextension sequencing reaction, in which allele-specific probes interrogate loci of interest and are fluorescently
labelled using dideoxynucleotides. These probes are designed to have different sizes and are subsequently resolved by electrophoresis and analysedb ya n
automated DNA sequencer. Thus, the identity of each locus is given by the position of its corresponding fluorescent peak in the spectrum, which is dictated by
the length of the extension primer.
B. Detailed view of the single-base extension reaction. The identity of the nucleotide(s) present at each locus is given by two parameters: the molecular weight
and the colour of the fluorescently labelled ddNTPs added to the allele specific probes during the extension step. Thus, mutant and wild-type alleles can be
distinguished based on the slightly different positions and on the distinct colours of their corresponding peaks. These two factors are used to establish the bins
used for automatic data analysis (described in the Supporting Information).
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We proﬁled 250 primary cancer samples representative of major
human malignancies, anddetecteda totalof 100 mutations in86
(34%) of the cases (Supporting Information Table S2). Of note,
the majority of these tumour samples (96%) were derived from
FFPE tissue. The most frequently mutated gene was KRAS,
across multiple tumour types, followed by EGFR, which was
detected in lung adenocarcinomas (Table 2 and Fig 3).
Consistent with previous reports (Subramanian & Govindan,
2008), KRAS mutations in lung cancer were strongly associated
with a history of smoking (89% of KRAS mutations were found
in patients that smoked >10packs/year), while the reverse was
true for EGFR, with 73% of EGFR-mutant tumours originating
from patients who had never smoked.
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Table 1. Cancer genes included in the assay and available targeted cancer therapies
Gene SNaPshot
coverage
Relevant drugs: launched (developer) Relevant drugs in clinical testing
(number of compounds)
1
APC 15% None None
BRAF 94%
Sorafenib (Bayer HealthCare
Pharmaceuticals, Onyx
Pharmaceuticals)
Raf inhibitors (4)
MEK inhibitors (12)
ERK inhibitor (1)
CTNNB1 74% None None
EGFR 69%
Gefitinib (AstraZeneca)
EGFR inhibitors (26)
Cetuximab (ImClone Systems, Merck
Serono, Bristol-Myers Squibb)
Erlotinib hydrochloride (Genentech, OSI
Pharmaceuticals, Roche)
Panitumumab (Amgen)
Nimotuzumab (YM BioSciences, Biotech
Pharmaceuticals, Oncoscience, Daiichi
Sankyo)
Lapatinib (GlaxoSmithKline)
FLT3 22%
Sorafenib (Bayer HealthCare
Pharmaceuticals, Onyx
Pharmaceuticals) FLT3 inhibitors (10)
Sunitinib (Pfizer)
JAK2 99% None JAK2 inhibitors (4)
KIT 24%
Imatinib mesylate (Novartis Oncology)
KIT inhibitors (11)
Sorafenib (Bayer HealthCare
Pharmaceuticals, Onyx
Pharmaceuticals)
Sunitinib (Pfizer)
KRAS 98% None
Raf inhibitors (4)
MEK inhibitors (12)
ERK inhibitor (1)
NOTCH1 9% None Notch1/Gamma-Secretase inhibitors (3)
NRAS 97% None
Raf inhibitors (4)
MEK inhibitors (12)
ERK inhibitor (1)
PIK3CA 76%
mTOR inhibitors:
Sirolimus (Wyeth Pharmaceuticals) PI3K inhibitors (10)
Everolimus (Novartis Pharmaceuticals)
PKB/AKT inhibitors (6)
Temsirolimus (Wyeth Pharmaceuticals)
mTOR inhibitors (13)
PTEN 15%
mTOR inhibitors:
Sirolimus (Wyeth Pharmaceuticals) PI3K inhibitors (10)
Everolimus (Novartis Pharmaceuticals) PKB/AKT inhibitors (6)
Temsirolimus (Wyeth Pharmaceuticals) mTOR inhibitors (13)
TP53 29% None None
The numbers on the second column reﬂect the frequency of somatic mutations described for each gene (COSMIC database v42 release) that are captured by
SNaPshot genotyping. The data on targeted agents was compiled using the Prous Science database (www.prous.com). Of note, many compounds have multiple
targets or overlapping activities.
1Cancer trials.
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Figure 2. Sensitivity assessment revealed the ability to detect low-level mutations. Two representative SNaPshot assays illustrate sensitivity evaluation. The
section on the left represents the multiplexed panel containing the assay of interest; the middle section is a magnified image of the SNaPshot assay being tested
and includes the bins used for automatic allele calling (described in the Supporting Information); and the section on the right represents traditional Sanger
sequencing analysis of the same samples. In both cases, the top panel shows genotyping data obtained for normal male genomic DNA (Promega, Madison, WI). In
the panels underneath, DNA derived from cancer cell lines harbouring specific mutations was serially diluted against the wild-type genomic DNA (Promega), as
specified by the percentage values on the left. Mutant alleles are indicated by arrows, and background signals are marked with asterisks. An in-depth view of
sensitivity assessment for these two assays is illustrated in Supporting Information Fig S3.
A. The A427 lung carcinoma cell line was used to detect the KRAS G12D mutation (nucleotide change 35G>A). Sensitivity was  3% and the SNaPshot panel
includes the following assays: (1) KRAS 35; (2) EGFR 2236_50del R; (3) PTEN 517; (4) TP53 733; (5) FLT3 2503; (6) PIK3CA 3139; (7) NOTCH1 4724 and (8)
NOTCH1 4802.
B. The NCI-H1975 lung adenocarcinoma cell line was used to identify the EGFR T790M mutation (nucleotide change 2369C>T). Assay sensitivity was  3% and
theSNaPshotpaneltestsfor:(1)KRAS34;(2)EGFR2235_49delF;(3)EGFR2369;(4)NRAS181;(5)PIK3CA1633;(6)CTNNB194and(7)CTNNB1121.Ascanbe
appreciated in the middle section, decreasing levels of ‘green’ mutant signal (arrows), absent from wild-type DNA (top panel), can be easily distinguished from
the nearby ‘red’ background peak (asterisk), which is also found in the assay run on the normal control (top panel). Of note, the EGFR c.2369C assay was
designed in the reverse orientation, thus the observed alleles are G (blue) for the wild-type and A (green) for the mutant.
150  2010 EMBO Molecular Medicine EMBO Mol Med 2, 146–158 www.embomolmed.orgThe speciﬁcity of SNaPshot genotyping was evaluated by
analysis of primary tumour samples and matching normal tissue
from the same individual. Figure 4 includes examples of
adenocarcinomas of the lung (Fig 4A) and pancreas (Fig 4B),
and of malignant melanoma (Fig 4C), and depicts the most
prevalent activating mutations in our data set for EGFR (L858R),
KRAS (G12V) and BRAF (V600E), respectively. The mutant allele
(arrow) is only detected in the tumour specimen and not in the
matching normal tissue, demonstrating the speciﬁcity of the test.
In general, our genotyping results were consistent with the
documented mutational prevalence for oncogenes, but we
observed lower than expected mutational frequencies for
tumour suppressors (Supporting Information Table S3). Slight
discrepancies between our observations and the reported
mutation frequencies for oncogenes included lower than
expected mutation prevalences for beta-catenin (CTNNB1)
and BRAF in pancreatic and colorectal tumours, respectively;
and higher than the reported frequencies for NRAS in colorectal
cancer. Surprisingly, the incidence of NRAS mutations in the
colorectal cancer population tested was threefold higher than
previously described. Interestingly, we also identiﬁed a number
of mutations and combination of mutations (marked by ‘‘a’’ in
Table 2) that are rare or not previously described in the
respective tumour types. Some of these less common events are
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Table 2. Somatic mutations detected by SNaPshot genotyping of primary
tumours
Tumour type Total no.
of cases
Mutations (no. of cases)
Breast 33 KRAS G12VþPIK3CA E545K (1)
a
PIK3CA H1047L (1)
PIK3CA H1047R (2)
TP53 R175H (1)
TP53 R248Q (1)
Chronic
myeloproliferative
disorder
10 JAK2 V617F (4)
Colorectal 30 APC R1114X (1)
BRAF V600E (1)
KRAS G12C (1)
KRAS G12D (2)
KRAS G12S (1)
KRAS G12V (2)
KRAS G12VþPIK3CA E545K (1)
KRAS G13D (1)
KRAS G13DþPIK3CA R88Q (1)
a
KRAS G13DþTP53 R273H (1)
a
NRAS G12D (2)
a
NRAS Q61HþTP53 R175H (1)
a
PI3KCA E545K (1)
TP53 R175H (1)
Lung 87 CTNNB1 S37FþEGFR
E746_A750del (1)
a
EGFR E746_A750del (6)
EGFR E746_A750delþEGFR
T790MþTP53 R175H (1)
a
EGFR L858R (4)
EGFR L858RþEGFR T790M (1)
KRAS G12A (2)
KRAS G12C (10)
KRAS G12D (1)
KRAS G12DþTP53 R248Q (1)
a
KRAS G12V (3)
KRAS G13D (1)
NRAS Q61LþTP53 R248P (1)
a
PIK3CA E542K (1)
TP53 R248Q (1)
TP53 R273L (1)
Melanoma 11 BRAF V600E (4)
BRAF V600M (1)
NRAS Q61L (1)
NRAS Q61R (1)
Pancreatic 23 KRAS G12D (2)
KRAS G12DþTP53 R175H (1)
a
KRAS G12R (2)
KRAS G12V (5)
KRAS G12VþTP53 R248Q (1)
a
Prostate 20 CTNNB1 S33C (1)
CTNNB1 S37YþPIK3CA E542K (1)
a
KRAS G13R (1)
a
Other 36 BRAF V600E (1)
a, unknown
primary, presumed breast
KRAS G12D (1), cervical
TP53 R306X (1)
a, thyroid
Hurthle cell carcinoma
aMutations or combination of mutations that are rare or not-previously
described in the corresponding tumour type.
Figure 3. Distribution of somatic mutations in primary human cancers.
Mutational profiling of 250 cancer specimens is depicted across tumour types
according to:
A. their mutational status and
B. the mutation frequency of individual genes.
www.embomolmed.org EMBO Mol Med 2, 146–158  2010 EMBO Molecular Medicine 151Report
Tumour genotyping for personalized cancer care
Figure 4. Profilingof primarytumours and matching normal tissue established assay specificity.Shown hereare three examples ofgenotyping dataobtained
using total nucleic acid extracted from normal (top) and tumour (middle) FFPE tissue from the same individual, and a no-DNA negative control (bottom). Of note,
the mutant allele (arrow) is only found in the tumour (middle panel).
A. Detection of the EGFR L858R (c.2573T>G) mutation in a case of lung adenocarcinoma. Assays: (1) EGFR 2236_50del F; (2) EGFR 2573; (3) CTNNB1 133;
(4) PIK3CA 1624 and (5) NRAS 35.
B. Identification of the KRAS G12V (c.35G>T) mutation in a pancreatic adenocarcinoma. Assays: (1) KRAS 35;(2) EGFR 2236_50del R; (3) PTEN 517; (4) TP53 733;
(5) FLT3 2503; (6) PIK3CA 3139; (7) NOTCH1 4724 and (8) NOTCH1 4802.
C. Detection of the BRAF V600E (c.1799T>A) mutation in melanoma. Assays: (1) EGFR 2235_49del R; (2) NRAS 38; (3) BRAF 1799; (4) NRAS 182; (5) PIK3CA 263;
(6) TP53 742; (7) CTNNB1 95 and (8) CTNNB1 122.
152  2010 EMBO Molecular Medicine EMBO Mol Med 2, 146–158 www.embomolmed.orgillustrated in Supporting Information Fig S6 and include the co-
occurrence of activating mutations in KRAS and PIK3CA in
breast cancer, which were proposed to be mutually exclusive
events based on cell line studies (Hollestelle et al, 2007), and of
beta-catenin and EGFR mutations in a rarely recognized case of
foetal-type lung adenocarcinoma (Nakatani et al, 2002).
Within the subset of events captured by our panel, our
observations were consistent with previous ﬁndings from
genome wide studies (Supporting Information Fig S7). The most
commonmutationsobservedincolorectalcancerwereC:GtoT:A
transitions, previously shown to be abundant in this tumour type
and a possible effect of dietary carcinogens (Sjoblom et al, 2006).
Moreover, consistent with previous reports, we identiﬁed C:G to
A:T transversions (34%) and C:G to T:A transitions (24%) as the
most frequent mutation classes in lung cancer (Ding et al, 2008).
C:G to A:T transversions have been associated with smoking and
are thought to be induced by tobacco smoke carcinogens (Slebos
et al, 1991). All C:G to A:T transversions detected in our lung
cancer population were found in smokers (Fig S7B), which is
likely in part due to the pattern of KRAS mutations commonly
seen in smokers. Finally, we identiﬁed a higher proportion of
mutations in smokers than in never-smokers for lung (49% vs.
28%) and pancreatic (67% vs. 13%) cancers, in agreement with
previously observed correlations between smoking and the
numberofgeneticchangesinthesetumourtypes(Blackfordetal,
2009; Ding et al, 2008).
Clinical application of genetic profiling
Out of all primary tumours examined, 62 cases were genotyped
as part of what has now become routine clinical testing at our
institution (Supporting Information Table S2). Exon 19 of the
EGFR gene is a hotspot for in-frame deletions, often found in
lung cancer and that have been associated with response to
EGFR TKI therapy (Lynch et al, 2004; Mok et al, 2009; Paez et al,
2004; Pao et al, 2004). Although the SNaPshot assay tests for the
two most common deletions in the EGFR intracellular domain,
due to the therapeutic implications of this region, mutational
proﬁling of clinical cases was complemented by a PCR-based
sizing assay designed to capture all deletions (or insertions) in
EGFR exon 19. For most cases (98%) there was concordance
between SNaPshot and the exon 19 sizing data, however, the
second approach identiﬁed one additional deletion in EGFR
which was not captured by SNaPshot genotyping (Supporting
Information Table S2).
In our early experience implementing this assay in a clinical
setting, approximately two to three weeks are required from the
time of test requisition until genotyping report ﬁnalization. We
thus refer to this as a ‘real-time’ assay, as oncologists ordering
the test will have access to their patients’ tumour mutational
proﬁling data in time to inﬂuence clinical decision making. In
these initial analyses, we have already observed that the
SNaPshot results have substantially impacted therapeutic
decisions. For lung cancer patients, detection of activating
mutations in EGFR will identify patients most appropriate for
ﬁrst-line treatment with EGFR TKI therapy (Kobayashi et al,
2005; Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004; Zhu et
al, 2008). Conversely, tumours harbouring KRAS mutations are
associated with lack of responsiveness to EGFR TKI treatment,
and such patients are advised to pursue other therapeutic
options (Pao et al, 2005b). Although mutational analysis for
these two genes is already widely viewed as the modern
standard of care, our genotyping effort uncovered a few
additional events, less commonly tested for, that also inﬂuenced
clinical decisions. Supporting Information FigS8A illustratesthe
case of a breast cancer patient with metastatic disease that had
progressedthroughallprevioustherapyregimens.Identiﬁcation
of the PIK3CA H1047L activating mutation in her tumour
promptedenrolmentinaclinicaltrialofanewPIK3CAinhibitor.
Supporting Information Fig S8B represents the case of a lung
cancer patient with an activating mutation in EGFR that had
previously responded to anti-EGFR therapy, but who recently
relapsed. Re-biopsy and genotyping of the recurrence revealed
the presence of the EGFR T790M mutation, which confers
resistance to ﬁrst-generation EGFR TKIs (Pao et al, 2005a). This
ﬁnding prompted subsequent therapy with an irreversible EGFR
TKI, which also targets the newly acquired T790M EGFR mutant
(Riely, 2008). Supporting Information Fig S8C is an example of
how SNaPshot genotyping can offer some insight into tumour
heterogeneity. Here, proﬁling of bilateral tumour masses in a
patient with lung cancer revealed two distinct genotypes. Our
results supported the clinical suspicion that this was not
metastatic disease, but rather two synchronous early stage
primary tumours. This interpretation provided a better prog-
nosis for the patient, and affected the consideration for pursuing
aggressive surgical therapy and adjuvant chemotherapy,
directly impacting the management of her disease.
Tofurtherinvestigatesample heterogeneitywithin theprimary
tumours evaluated for clinical testing, we re-examined all mutant
cases and compared the levels of mutant alleles identiﬁed by
SNaPshotgenotypingwith the extent ofstromalcontaminationin
each original tumour specimen. As shown in Supporting
Information Table S4 the extent of stromal contamination
(column 2), and the levels of mutant alleles (column 3) are
distinct for different tumour specimens, which is most likely
reﬂecting our inability to accurately predict stromal contamina-
tion in a tridimensional tumour specimen, based on the
histological evaluation of a single tumour section. In addition,
some of these discrepancies may be due to tumour heterogeneity
and the presence of activating mutations within variable subsets
of tumour cell populations. Concerns with tumour heterogeneity
underscore the importance of using highly sensitive mutation
detection methods. This matter has been widely appreciated,
particularly for mutations that confer resistance to targeted
therapeutics where the detection of minor resistant clones, either
intheprimarytumourorduringthecourseoftreatment,iscritical
to predict response (Maheswaran et al, 2008; Marchetti et al,
2009; Yung et al, 2009). By contrast, the clinical implications of
identifying low levels of drug-sensitizing mutations are currently
unknown. To begin to address this issue, we examined whether
patients with low abundance EGFR sensitizing mutations
responded to EGFR TKIs. Within this small cohort, we identiﬁed
two patients (NA09-129 and NA09-184) with low levels (<20%)
of EGFR exon 19 deletions both of whom achieved a clinical
responsetoEGFRTKItherapy(SupportingInformationTableS4).
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matter, our preliminary observations suggest that the use of
targetedagentsmaybehelpfulevenincaseswherethesensitizing
mutations are restricted to smaller clones of the tumour cell
population. Importantly, our ﬁndings indicate that highly
sensitive detection methods will be fundamental in identifying
these patients.
DISCUSSION
The conventional approach of treating cancer according to
histological parameters and tissue of origin is increasingly
accommodatingmoleculargeneticinformationderivedonacase-
by-case basis. As a step towards personalized cancer medicine,
our goal was to develop a high-throughput genetic proﬁling
platform to rapidly query resection or biopsy specimens for
relevantgeneticchanges inatimeandcost-effectivemanner, and
to help direct the administration of available targeted therapies.
To maximize the clinical utility of our assay, we: (1) focused
predominantly on genes targeted by FDA-approved therapies or
by therapeutics in clinical trials; and (2) sought to develop a
clinical test that could be easily adopted by many laboratories.
The tumour genotyping assay described here is currently
being applied for real-time testing of patient samples, and uses
expertise and infrastructure already present in most clinical
settings. We found it to be highly sensitive and speciﬁc, and to
perform very well with nucleic acid extracted from FFPE tissue,
which is a practical requirement for broad implementation by
pathology departments. The system is modular, so as more
targeted drugs become available and more predictors of
response are identiﬁed, new assays can be designed and
introduced to existing panels. In addition to the high quality of
the data, a major advantage of using SNaPshot technology for
tumour genotyping is the lack of need for an upfront investment
in high-tech instrumentation not commonly available even in
modern clinical laboratories. For example, the minimum cost of
equipment for some of the current multiplexed allele-targeted
technologies and next-generation sequencing platforms,
approaches several hundreds of thousands of dollars. Due to
the multiplexing features of the SNaPshot technique, the tissue
requirements and cost-per-assay are also low. Our data suggest
that signal detection by the SNaPshot system, which combines
capillaryelectrophoresis withtheabilitytoidentifyfourpossible
ﬂuorescently labelled extension products, offers added advan-
tages when compared to other methods. For instance, while in
array-basedsingle ﬂuorophore-detecting technologies oneassay
tests for the presence or absence of a single mutant allele, each
SNaPshot assay queries all three possible mutant variants at
once. Also, in contrast to mass spectrometry-based methods
(which rely on molecular weight for allele recognition), since
the SNaPshot method identiﬁes different nucleotide variants at
thesamelocusnotonlybytheirmassbutalsobytheircolour,an
additional parameter is available to help distinguish between
wild-type, mutant, and background signals. This point is
illustrated in Supporting Information Fig S9 which provides a
directcomparisonbetweenSNaPshotandSequenomMassArray
assays. Finally, while the use of next-generation sequencing
may ultimately replace current platforms for tumour genotyp-
ing, it will likely be several years before the technology and
computational infrastructure become affordable and are mature
enough for validation and generalized clinical use. For a more
detailed discussion of the costs, workﬂow and tissue require-
ments of the SNaPshot platform and its comparison with other
technologies please refer to Supporting Information.
ThemainlimitationoftheSNaPshotmethodappearstobethe
number of reactions that can be multiplexed together (plex
level), whichappearstobeoptimal below 10.Whileotherallele-
speciﬁc platforms usually use much higher plex levels for
SNP-detection, when employed for rare mutation proﬁling, their
plex level is also lower than 10 (Thomas et al, 2007). Since there
is a limit to the number of assays that can be performed on
scarce tumour biopsies, as with other targeted sequencing
strategies, SNaPshot genotyping is best suited to test for genes
affected by point mutations, insertions or deletions at only a few
hotspots. Our assay design has a better coverage for oncogenes
than for tumour suppressors (Table 1), as the latter tend to be
mutated at many more sites than the former. Accordingly,
genotyping of primary tumours was overall consistent with
reported data for the oncogenes, but captured lower mutation
frequencies than what has been documented for most tumour
suppressors (Supporting Information Table S3). Slight discre-
pancies between our observations and the reported mutation
frequencies for oncogenes included both lower (CTNNB1 and
BRAF) and higher (NRAS) than expected mutation levels within
speciﬁc cancer types. This variability most likely reﬂects
differences in tumour sub-populations and sample sizes rather
than the performance of the assay.
In this era of genomic medicine, one of the most debated
questions regarding tumour proﬁling is which cancer genes and
mutations should be tested. If time and cost were not an issue
andiftissuequalityandquantity werenotalimitingfactor,most
would agree that more information is usually better. Despite the
challenges of interpreting highly complex data sets, a complete
molecular picture of each tumour should provide the best
resource to make informed treatment decisions and establish
meaningful correlations between response to therapy and
speciﬁc genetic signatures. Tumour proﬁling has advanced
signiﬁcantly in the past decade and will continue to evolve.
However, if we want to improve cancer prospects today and
until next-generation sequencing options become economically
viable and rapid enough to address the time constraints of
clinical decision making, highly multiplexed allele-speciﬁc
platforms like the one presented here will be invaluable clinical
resources. We selected the cancer mutations most likely to have
immediate clinical impact, either because they are targeted by
FDA-approved drugs or by therapeutic agents in clinical trial.
Ideally, the clinical application of targeted mutational
proﬁling will be complemented by additional approaches to
provide a more comprehensive picture of each individual
cancer, which would include alterations in gene copy number,
karyotype information and chromosomal rearrangements such
as translocations and large insertions or deletions. Such
analyses will require the application of additional technologies
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the EGFRvIII mutation commonly observed in human glioblas-
toma, results in a constitutively active receptor with an in-frame
truncation within its extracellular ligand-binding domain, and is
of relevance for targeted therapy (Pedersen et al, 2001). While
the mutation mechanisms leading to EGFRvIII are diverse,
ranging from large deletions of genomic DNA to point mutations
that affect splicing, the end product is a single mRNA splice
variant lacking exons 2–7, making it an ideal candidate for
detection by allele-speciﬁc assays like the one described herein.
Such a test would require slight adaptation of the protocol to
include a cDNA synthesis step, and possibly the use of a better
quality tissue source than the highly fragmented nucleic acid
extracted from archived FFPE tumour tissue that was employed
in the present study.
It is suspected that deregulation of a core of common
signalling pathways is one of the major underlying causes
driving human carcinogenesis (Jones et al, 2008). Therefore, we
decided to apply the same broad genotyping platform to all
tumours, rather than restricting the analysis to focused
mutational panels for speciﬁc cancer types. We hope that this
approach will identify novel treatment opportunities for a
broadersetofmalignancies.Tothatextent,ourstudyuncovered
a number of mutations and mutation co-occurrences that had
not been previously appreciated in the tumour types tested
(Table 2). We suspect that clinical application of mutation
proﬁling programs such as this one, across multiple malig-
nancies, will swiftly impact disease management not only of
common cancers but also of rare tumours, which have to date
received less comprehensive attention. Moreover, while some
current examples have established a convincing foundation for
using speciﬁc mutations as predictors of response to selective
agents(e.g. EGFRkinasemutationspredicttumour sensitivityto
geﬁtinib and erlotinib, and KRAS mutations confer resistance to
EGFR TKIs) (Mok et al, 2009; Pao et al, 2005b) the future
landscape of cancer therapy is likely to be less simple. As novel
therapeutic approaches contemplate the use of multiple agents
and of multi-targeted drugs, the correlations between speciﬁc
mutational genotypes and sensitivity or resistance to treatment
will probably be more complex. Genetic proﬁling strategies will
be essential to dissect these intricate connections and will likely
play an increasingly important role in cancer management.
Going forward, determining the optimal application of novel
agents will require carefully designed clinical trials which
integrate tumour molecular analysis in both up-front patient
selection and retrospective correlative analyses.
Finally, most genes included in our panel are targeted by
currently available drugs making them ideal candidates for
genetic proﬁlinghowever,withthe exceptionofKRASand EGFR,
the full clinical implications of many of the mutations tested by
our assay are still under investigation. Clinical questions of
interest include not only the efﬁcacy of novel agents in clinical
trials, but also the viability of using a given drug to ﬁght different
cancer types with similar genetic abnormalities, and the optimal
treatment of heterogeneous tumours harbouring different levels
of the target mutation. The lack of established treatment
algorithms based on results of genetic proﬁling needs to be
clearlyconveyedtopatientsundergoingtesting,whichinourcase
is accomplished by a consent form and counselling session with
background information about the test. Thus, before giving
permission to have their tumour tested, patients understand that
molecular proﬁling may (or may not) provide information that
could helpthemand their doctordecidewhichtherapiescould be
most or least successful in treating their tumour, as either part of
standard therapy or as part of research studies that may be of
interest to them. The costs of testing are billed to the patient’s
insurance company and issues related to reimbursement are
addressed by hospital-wide policies in the same way as with any
other clinical test or procedure.
Targeted cancer therapy is revolutionizing clinical oncology
and driving efforts to integrate tumour molecular analysis in
clinical decision making. The EGFR story in NSCLC has
demonstrated that genotype-driven treatment choices affect
patient outcomes. Robust and practical genotyping strategies
such as the one described here will be instrumental in moving
forward the optimal application of targeted therapies. Such
approaches will undoubtedly see increasing application in the
selection of patients for early-stage clinical trials, providing the
potential for better response rates and improved interpretation
of trial results. Tumour genetic analysis therefore holds great
promise to make personalized cancer care a reality.
MATERIALS AND METHODS
Specimen collection
We tested 250 primary cancer samples spanning 26 human
malignancies, which included: lung cancer (n¼87), breast cancer
(n¼33), colorectal cancer (n¼30), pancreatic cancer (n¼23),
prostate cancer (n¼20), melanoma (n¼11), chronic myeloprolifera-
tive disease (n¼10), cholangiocarcinoma (n¼6), gastric cancer
(n¼4), ovarian cancer (n¼3), salivary gland cancer (n¼3) and
thyroid cancer (n¼3) among others. Sixty-two of these primary
tumour samples were evaluated for official clinical testing, and
included 52 lung adenocarcinomas, most of them small core biopsies
with very limited tissue. For haematopoietic malignancies, spare DNA
that had been previously extracted from patient blood for clinical
testing was obtained from the Massachusetts General Hospital (MGH)
Molecular Diagnostics Laboratory. For solid tumours, formalin-fixed
paraffin-embedded (FFPE) tumour blocks were obtained from the MGH
archives. All samples were collected with institutional review board
approval. Histological examination of haematoxylin and eosin-stained
slides derived from FFPE samples was performed by a pathologist (AJI)
and assessed for the presence of tumour. Available tumour tissue was
manually macrodissected from serial 5mm unstained sections, or cored
from the paraffin block using a 1.5mm dermal punch. Total nucleic
acid was extracted from FFPE material using a modified FormaPure
System (Agencourt Bioscience Corporation, Beverly, MA) on a custom
Beckman Coulter Biomek NX
P workstation. Blood-derived DNA was
extracted using the QIAamp Blood kit (Qiagen, Inc., Valencia, CA).
Assay design
We evaluated the COSMIC (Bamford et al, 2004) database and
PubMed to select a panel of genes and loci previously reported to be
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13 cancer genes and designed 58 assays to test for individual
mutational events, which included: 1 insertion, 3 deletions and 52
substitutions (Supporting Information Table S1). Genomic position and
sequencing information for all mutation sites were collected using the
RefSeq gene sequences obtained using the human genome browser
from the University of California Santa Cruz (UCSC), NCBI build 36.1.
Primers for multiplexed PCR amplification were designed using Primer
3 software. Since FFPE tissue can be highly fragmented and of poor
quality, design parameters restricted amplicon length to a maximum
of 200nt. All amplification primers (Supporting Information Table S5A)
include a 10nt long 50 anchor tail (50-ACGTTGGATG-30) and the final
PCR products range in length between 75 and 187nt. The extension
primer probes (Supporting Information Table S5B) were designed
manually, according to the ABI PRISM SNaPshot Multiplex Kit protocol
recommendations (Life Technologies/Applied Biosystems, Foster City,
CA) and using primer analysis tools available through the Primer 3 and
Integrated DNA Technologies (IDT, Coralville, IA) web interfaces.
Optimal conditions for multiplexed assays were determined empiri-
cally and are summarized in Supporting Information Table S6.
As part of the design rationale, we included assays covering four
adjacent loci that are commonly mutated in the therapeutically
relevant KRAS and NRAS oncogenes (for both genes we are targeting
nucleotide positions: 34G, 35G, 37G and 38G). Due to the close
proximity of these sites, to avoid compromising assay sensitivity due
to primer competition, we decided to assay each of them in an
independent panel. In addition, due to the extreme sequence similarity
between KRAS and NRAS, to avoid non-specific results, we segregated
the assays for the two genes into individual multiplexed reactions. We
thus started with eight panels, which were populated with the 58
assays outlined in Supporting Information Table S1. Many of these
genes and assays are clinically relevant. In addition, since the costs of
running the assay (regarding tumour material and the actual price per
assay) are mainly dictated by the number of panels, we decided to
also include a set of common mutations affecting critical cancer genes
for which a therapeutic agent is still currently unavailable. We
hope that the addition of these less ‘clinically relevant’ mutations will
still be useful in a clinical setting, as we may find them to correlate
with a better or worse prognosis or to influence response to specific
therapies, and thus contribute to better cancer care in the future.
SNaPshot genotyping
The Applied Biosystems (ABI) Prism
1 SNaPshot
1 Multiplex system was
originally developed to detect single nucleotide polymorphisms (SNPs)
(Lindblad-Toh et al, 2000) (Fig 1). Multiplexed PCR was performed in a
volume of 10ml, containing 0.5U of Platinum Taq polymerase
(Invitrogen, Carlsbad, CA, USA), 30nmol of MgCl2, 3nmol of dNTPs
(Invitrogen), amplification primers (IDT) as specified in Supporting
Information Table S6A, and ideally either 20ng of genomic DNA or
60ng of total nucleic acid. When the amount of tissue was limiting,
multiplexed PCR was performed with as low as 5ng of total nucleic
acid. Thermocycling was performed at 958C for 8min, followed by 45
cycles of 958C for 20s, 588C for 30s and 728C for 1min, and one last
cycle of 728C for 3min. Excess primers and unincorporated dNTPs were
inactivated using 3.3U of shrimp alkaline phosphatase (USB, Cleveland,
OH) and 2.7U of exonuclease I (USB) for 60min at 378C, followed by
15min at 758C for enzyme inactivation. The primer extension reaction
was performed in a volume of 10ml, containing 3ml of PCR product,
2.5ml of SNaPshot Multiplex Ready Reaction mix, and the appropriate
cocktail of PAGE-purified extension primers (IDT; Supporting Informa-
tion Table S6B). Cycling conditions were 968C for 30s, followed by 25
cycles of 968C for 10s, 508C for 5s and 608C for 30s. After treatment
with 2U of shrimp alkaline phosphatase, 0.5ml of labelled extension
products were mixed with Hi–Di Formamide and 0.2mlo fG e n e S c a n -
120LIZ size standard (Life Technologies/Applied Biosystems) to a final
volume of 10ml. Following denaturation at 958Cf o r5 m i n ,t h e
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PROBLEM:
Cancer cells harbour genetic abnormalities that give them a
survival and proliferative advantage. These are also the cancer’s
Achilles heel, as the tumour becomes highly dependent on them
to grow. ‘Smart drugs’ are being developed to target specific
genetic abnormalities and only the tumours harbouring the
targeted mutations will respond to each drug. One of the main
challenges facing the oncology community today is how to
efficiently match each tumourwith the right therapy, and give all
cancer patients the best shot at fighting their disease.
RESULTS:
We developed and extensively validated a simple and flexible
multiplexed tumour genotyping assay that detects common
mutations in some of the most important cancer genes (including
EGFR, KRAS, NRAS, BRAF and PIK3CA), many of which activate
cancer signalling pathways targeted by currently available ‘smart
therapies’. Our analysis included the genetic profiling of 250
primary tumours, was consistent with the documented oncogene
mutational spectrum and demonstrated that the SNaPshot
system is fast, highly sensitive and very robust.
IMPACT:
Over the past year we have consistently profiled lung cancers
presented to the MGH. The test was recently expanded to
colorectal malignancies and will soon be offered to all incoming
cancer patients. We shared our protocols with other laboratories
thathave nowalsoquicklyimplementedand adaptedthissystem
to their particular needs, which has further convinced us of its
broad applicability and its potential to personalize cancer care
and impact therapeutic decisions in a large scale.
156  2010 EMBO Molecular Medicine EMBO Mol Med 2, 146–158 www.embomolmed.orgextension products were resolved by running on 36cm long capillaries
in an automatic sequencer (ABI PRISM 3730 DNA Analyser, Life
Technologies/Applied Biosystems), according to the SNaPshot default
settings established by ABI. Data analysis was performed with
GeneMapper Analysis Software version 4.0 (Life Technologies/Applied
Biosystems) using the automatic calling parameters described in the
Supporting Information.
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